BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

Nine months after partnering to test a BRAF-MEK combination therapy, BeiGene and Pfizer spinout SpringWorks are collaborating again, this time forming a joint venture to develop a BeiGene BRAF inhibitor that could lead to combination therapies with SpringWorks' MEK inhibitor PD-0325901.

MapKure LLC gained an exclusive license from BeiGene Ltd. (NASDAQ:BGNE;

Read the full 516 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE